Influence of coenzyme Q10 on periodontal inflammation - a randomized controlled trial

Not Applicable

• Conditions: K05.3; Chronic periodontitis

• Registration Number: DRKS00023434
• Lead Sponsor: Dr. med. Schütze GmbH

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2020-10-30
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

• gender male or female, age between 40 and 70 years
• ability to give informed consent
• voluntary participation
• caries-free, sufficently treated teeth (D-T = 0)
• generalized periodontitis stage III-IV
• periodontal treatment need according to periodontal chart
• at least 20 remaining teeth
• BOP = 30%, PD = 5mm at = 35% of the probing sites
• pretreatment: 2 professional teeth cleaning with an interval of 2-3 weeks before the periodontal chart

Exclusion Criteria

• planned adjuvant antibiotic treatment in the periodontal treatment
• less than 20 remaining teeth
• BOP < 30 %
• last systematic scaling and root planing in the last 24 months
• smoker
• antibacterial, anti-inflammatory or immunosuppressive medication in the last 3 months before and during the study
• local antiseptic or antibacterial treatment in the last 4 weeks before and during the study
• known intolerance against ingredients of the used spray, toothpaste or other in the study used materials
• patients with significantly reduced / missing fine motor skills
• not feasible investigation due to poor general condition
• patients with significantly reduced salivation/ xerostomia
• patients with dementia
• immunosuppressed patients: transplanted organs, autoimmune disease (e.g. chronical intestine diseases, rheumatoid arthritis
• hepatitis A/B/C, tuberculosis, HIV (upon request)
• diabetes mellitus
• participants that would need an antibiotic prophylaxis (e.g. risc for endocarditis, immunosuppression)
• participants with epileptic or neurological disorders
• addicts
• pregnant or nursing women (upon request)

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Bleeding on Probing (BOP) and pocket depths (PD) after 6 weeks, 3, 6 and 12 months

Secondary Outcome Measures

Name	Time	Method
attachementlevel (AL), papillary bleeding index (PBI), gingiva index (GI), side effects, rating by the patient